← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
Cilostazol tinnitus pilot study
Also known as: Cilostazol, Pletaal, CITI-ESR, AMC-2010-0800, KCT0000128, NCT01378650
Investigator-led study
Sponsor / Institution
Investigator-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Interventional/NA
Status
Completed
Target Gene
—
Route / Mode
Oral tablet
Confidence
82%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
South Korea
Population
adult, tinnitus, chronic-tinnitus, investigator-led
Trial IDs
1
Mechanism
PDE3 inhibitor evaluated as a short-course tinnitus treatment based on a cochlear blood-flow hypothesis.
Indications
Notes
ClinicalTrials.gov identifies Jong Woo Chung/Asan Medical Center as the sponsor-investigator and Korea Otsuka as an industry collaborator. This should not be presented as an Otsuka-owned tinnitus program.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, populationTags...
IDs: NCT01378650, KCT0000128, CITI-ESR
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyindustry-collaborator-not-primary-sponsorno-posted-results-confirmed
Related Programs
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
ACOU085 by Acousia Therapeutics
Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2
CIL001 (Paliroden) by Cilcare
Company: Cilcare SAS · Small Molecule · Phase 1/2